Advertisement

PentaVision

Retinal Physician

Article

16-Week Data From SALWEEN Fill the Gap for Patients With PCV

By week 16, average BCVA gain was slightly more than seven letters and CST was just over 400 μm.

Gemmy Cheung, MBBS, FRCOphth, FAMS, MCIMichael A. Singer, MD
Retinal Physician March 17, 2025

Clinical Scorecard: 16-Week Data From SALWEEN Fill the Gap for Patients With PCV

At a Glance

CategoryDetail
ConditionPolypoidal Choroidal Vasculopathy (PCV)
Key MechanismsEfficacy and safety of faricimab (Vabysmo) in treating PCV
Target PopulationPatients diagnosed with PCV
Care SettingOngoing clinical trial across eight to nine regions in Asia

Key Highlights

  • Average BCVA gain of slightly more than seven letters by week 16
  • CST reduction to just over 400 μm after initial injections
  • Polyp closure rate at week 16 is 51%
  • More than 80% of eyes had no active polyps
  • Trial follows a treat-and-extend protocol for retreatment intervals

Guideline-Based Recommendations

Diagnosis

  • Diagnosis based on clinical assessment and imaging techniques such as ICG and OCT

Management

  • Initial treatment with four monthly injections of faricimab, followed by assessments and possible extension of treatment intervals

Monitoring & Follow-up

  • Regular assessments of BCVA, CST, and disease activity at specified intervals

Risks

  • Potential for disease activity to return, necessitating shorter retreatment intervals

Patient & Prescribing Data

135 patients diagnosed with PCV enrolled in the SALWEEN trial

Faricimab shows promising results in improving BCVA and reducing CST in PCV patients

Clinical Best Practices

  • Utilize a treat-and-extend protocol based on disease stability
  • Monitor for disease activity using BCVA and CST as key indicators
  • Consider ICG findings for anatomical assessment but not as the sole determinant for treatment intervals

References